Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | Eftilagimod alfa and pembrolizumab in patients with squamous head and neck carcinoma

Eftilagimod alfa is a soluble LAG-3 protein that improves antigen presentation by interacting with major histocompatibility complex class II (MHCII). Irene Brana, MD, Vall d’Hebron University Hospital and Institute of Oncology (VHIO), Barcelona, Spain, discusses the updated results of a Phase II trial (NCT03625323) investigating the efficacy of eftilagimod alfa and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma. Eftilagimod alfa/pembrolizumab achieved a high overall response rate (ORR), almost double that of pembrolizumab found in the KEYNOTE-040 trial (NCT02252042); the highest response rate was found in patients with tumor proportion scores (TPSs) greater than 1. These promising findings will facilitate the trailing of eftilagimod alfa/pembrolizumab as a first-line treatment in metastatic squamous head and neck carcinoma and in patients with varying TPSs. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.